Hematologic Oncology Update

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma.  CME information and select publications here .

Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia.  CME information and select publications here

Dr Joshua Brody from The Tisch Cancer Institute in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from The University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. CME information and select publications  here .

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of d...

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.

Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Ketterin...

Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current...

Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data fro...

Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.

Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.

Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria.

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma.

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.

Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.

Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.

Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.

Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.

Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.